3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
40
Carcinoma, Non-Small-Cell Lung
32
Colorectal Neoplasms
27
Ovarian Neoplasms
23
Neoplasms
23
Lung Neoplasms
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Pancreatic Neoplasms
17
Leukemia, Myeloid, Acute
16
Head and Neck Neoplasms
16
Lymphoma, Non-Hodgkin
15
Neoplasm Metastasis
14
Fallopian Tube Neoplasms
14
Glioblastoma
13
Esophageal Neoplasms
12
Rectal Neoplasms
11
Lymphoma
11
Squamous Cell Carcinoma of Head and Neck
10
Central Nervous System Neoplasms
10
Carcinoma, Ovarian Epithelial
10
Recurrence
9
Melanoma
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Follicular
9
Leukemia
9
Stomach Neoplasms
8
Prostatic Neoplasms
8
Lymphoma, Mantle-Cell
7
Lymphoma, B-Cell, Marginal Zone
7
Liver Neoplasms
7
Interventions
pembrolizumab
25
Gemcitabine
21
Nivolumab
17
Cisplatin
17
atezolizumab
14
Carboplatin
11
avelumab
9
vinflunine
7
Ipilimumab
7
Paclitaxel
6
Docetaxel
5
enfortumab vedotin
4
cabazitaxel
4
Pemetrexed
4
Mitomycin
4
cabozantinib
3
Taxes
3
Rogaratinib
3
Magnetic Resonance Spectroscopy
3
Injections
3
Albumin-Bound Paclitaxel
3
tremelimumab
2
sacituzumab govitecan
2
pemigatinib
2
niraparib
2
lenvatinib
2
bempegaldesleukin
2
apatorsen
2
XRP6258
2
Vitamin D
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Transitional Cell
×
Drug Therapy
×
Clear all
NCT03410693
2022-09-28
FORT-1
Bayer
Phase 2/3
Completed
175 enrolled
19 charts